Relapsing remitting multiple sclerosis Trials in Katowice, Poland
Conditions / Relapsing remitting multiple sclerosis / Katowice, Poland
Relapsing remitting multiple sclerosis has been the subject of sustained clinical investigation across multiple research sites.
21 total trials for this combination
Showing top 10 of 21 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00420212 | Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE3 |
| NCT01838668 | An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) | COMPLETED | PHASE3 |
| NCT01064401 | Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE3 |
| NCT03093324 | A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 | COMPLETED | PHASE3 |
| NCT00835770 | BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) | COMPLETED | PHASE3 |
| NCT01797965 | Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 | TERMINATED | PHASE3 |
| NCT00297232 | Natalizumab (Tysabri) Re-Initiation of Dosing | TERMINATED | PHASE3 |
| NCT00451451 | Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE3 |
| NCT01067521 | A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo | COMPLETED | PHASE3 |
| NCT01963611 | Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) | TERMINATED | PHASE2 |